Global preventive vaccines market will reach $80.47 billion by 2026, growing by 11.26% annually over 2020-2026 owing to increasing healthcare expenditure, new development of the vaccines, and rising need for preventive vaccines especially new COVID-19 vaccines.
Highlighted with 110 tables and 84 figures, this 207-page report “Global Preventive Vaccines Market 2020-2026 by Vaccine Type, Disease, Administration, Patient, and Region: COVID-19 Impact and Growth Opportunity” is based on a holistic research of the entire global preventive vaccines market and all its sub-segments through extensively detailed classifications. Profound analysis and assessment are generated from premium primary and secondary information sources with inputs derived from industry professionals across the value chain. The report is based on studies on 2016-2019 and provides estimate/forecast from 2020 till 2026 with 2019 as the base year. (Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.)
In-depth qualitative analyses include identification and investigation of the following aspects:
• Market Structure
• Growth Drivers
• Restraints and Challenges
• Emerging Product Trends & Market Opportunities
• Porter’s Fiver Forces
The trend and outlook of global market is forecast in optimistic, balanced, and conservative view by taking into account of COVID-19. The balanced (most likely) projection is used to quantify global preventive vaccines market in every aspect of the classification from perspectives of Vaccine Type, Disease, Administration, Patient, and Region.
Based on Vaccine Type, the global market is segmented into the following sub-markets with annual revenue ($ mn) for 2016-2026 included in each section.
• Live/Attenuated Vaccines
• Inactivated Vaccines
• Subunit Vaccines
• Toxoid Vaccines
• Conjugate Vaccines
• Recombinant Vector Vaccines
• Other Vaccines
Based on Disease, the global market is segmented into the following sub-markets with annual revenue ($ mn) for 2016-2026 included in each section.
• Vaccines for Pneumococcal Disease
• Vaccines for Poliovirus
• Vaccines for Hepatitis
• Vaccines for Influenza
• Vaccines for Measles, Mumps, and Rubella (MMR)
• Vaccines for Varicella
• Vaccines for Human Papilloma Virus
• Vaccines for COVID-19
• Vaccines for Other Diseases
Based on Administration, the global market is segmented into the following sub-markets with annual revenue ($ mn) for 2016-2026 included in each section.
• Intramuscular Route
• Subcutaneous Route
• Oral Route
• Intravenous Injection
• Other Administration Routes
Based on Patient, the global market is segmented into the following sub-markets with annual revenue ($ mn) for 2016-2026 included in each section.
• Pediatric Vaccines
o Pneumococcal
o Measles, Mumps, and Rubella (MMR)
o Varicella
o Hepatitis
o Poliovirus
o Haemophilus Influenzae B (HIB)
o Other Diseases
• Adult Vaccines
o Influenza
o Cervical Cancer
o Hepatitis
o Zoster
o Other Diseases
Geographically, the following regions together with the listed national/local markets are fully investigated:
• APAC (Japan, China, South Korea, Australia, India, and Rest of APAC; Rest of APAC is further segmented into Malaysia, Singapore, Indonesia, Thailand, New Zealand, Vietnam, Taiwan, and Philippines)
• Europe (Germany, UK, France, Spain, Italy, Russia, Rest of Europe; Rest of Europe is further segmented into Netherlands, Switzerland, Poland, Sweden, Belgium, Austria, Ireland, Norway, Denmark, and Finland)
• North America (U.S., Canada, and Mexico)
• South America (Brazil, Colombia, Argentina, Rest of South America)
• MEA (Saudi Arabia, UAE, Egypt)
For each region and key country, detailed analysis and data for annual revenue ($ mn) are available for 2016-2026. The breakdown of all regional markets by country and split of key national markets by Vaccine Type, Disease, and Route of Administration over the forecast years are also included.
The report also covers current competitive scenario and the predicted trend; and profiles key vendors including market leaders and important emerging players.
Specifically, potential risks associated with investing in global preventive vaccines market are assayed quantitatively and qualitatively through GMD’s Risk Assessment System. According to the risk analysis and evaluation, Critical Success Factors (CSFs) are generated as a guidance to help investors & stockholders identify emerging opportunities, manage and minimize the risks, develop appropriate business models, and make wise strategies and decisions.
Key Players (this may not be a complete list and extra companies can be added upon request):
AstraZeneca plc
Bavarian Nordic A/S
China National Biotec Group Company Ltd.
CSL Ltd.
Daiichi Sankyo Co. Ltd
Emergent BioSolutions Inc.
GlaxoSmithKline plc
Johnson & Johnson
Merck & Co.
Moderna Inc.
Novavax, Inc.
Pfizer Inc.
Sanofi SA
Takeda Pharmaceutical Co. Ltd.
(Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.)
1 Introduction 9
1.1 Industry Definition and Research Scope 9
1.1.1 Industry Definition 9
1.1.2 Research Scope 10
1.2 Research Methodology 13
1.2.1 Overview of Market Research Methodology 13
1.2.2 Market Assumption 14
1.2.3 Secondary Data 14
1.2.4 Primary Data 14
1.2.5 Data Filtration and Model Design 15
1.2.6 Market Size/Share Estimation 16
1.2.7 Research Limitations 17
1.3 Executive Summary 18
2 Market Overview and Dynamics 21
2.1 Market Size and Forecast 21
2.1.1 Impact of COVID-19 on World Economy 23
2.1.2 Impact of COVID-19 on the Market 25
2.2 Major Growth Drivers 27
2.3 Market Restraints and Challenges 30
2.4 Emerging Opportunities and Market Trends 33
2.5 Porter’s Fiver Forces Analysis 37
3 Segmentation of Global Market by Vaccine Type 41
3.1 Market Overview by Vaccine Type 41
3.2 Live/Attenuated Vaccines 43
3.3 Inactivated Vaccines 44
3.4 Subunit Vaccines 45
3.5 Toxoid Vaccines 46
3.6 Conjugate Vaccines 47
3.7 Recombinant Vector Vaccines 48
3.8 Other Vaccines 49
4 Segmentation of Global Market by Disease 50
4.1 Market Overview by Disease 50
4.2 Vaccines for Pneumococcal Disease 52
4.3 Vaccines for Poliovirus 53
4.4 Vaccines for Hepatitis 54
4.5 Vaccines for Influenza 55
4.6 Vaccines for Measles, Mumps, and Rubella (MMR) 56
4.7 Vaccines for Varicella 57
4.8 Vaccines for Human Papilloma Virus 58
4.9 Vaccines for COVID-19 59
4.10 Vaccines for Other Diseases 62
5 Segmentation of Global Market by Administration 63
5.1 Market Overview by Administration 63
5.2 Intramuscular Route 65
5.3 Subcutaneous Route 66
5.4 Oral Route 67
5.5 Intravenous Injection 68
5.6 Other Administration Routes 69
6 Segmentation of Global Market by Patient 70
6.1 Market Overview by Patient 70
6.2 Pediatric Vaccines 72
6.3 Adult Vaccines 74
7 Segmentation of Global Market by Region 76
7.1 Geographic Market Overview 2020-2026 76
7.2 North America Market 2020-2026 by Country 80
7.2.1 Overview of North America Market 80
7.2.2 U.S. 83
7.2.3 Canada 88
7.2.4 Mexico 91
7.3 European Market 2020-2026 by Country 94
7.3.1 Overview of European Market 94
7.3.2 UK 97
7.3.3 France 100
7.3.4 Germany 103
7.3.5 Spain 106
7.3.6 Italy 109
7.3.7 Russia 112
7.3.8 Rest of European Market 115
7.4 Asia-Pacific Market 2020-2026 by Country 117
7.4.1 Overview of Asia-Pacific Market 117
7.4.2 China 120
7.4.3 Japan 123
7.4.4 India 127
7.4.5 Australia 130
7.4.6 South Korea 133
7.4.7 Rest of APAC Region 136
7.5 South America Market 2020-2026 by Country 138
7.5.1 Argentina 141
7.5.2 Brazil 144
7.5.3 Colombia 147
7.5.4 Rest of South America Market 150
7.6 MEA Market 2020-2026 by Country 151
7.6.1 UAE 154
7.6.2 Saudi Arabia 157
7.6.3 Egypt 160
7.6.4 Other National Markets 163
8 Competitive Landscape 164
8.1 Overview of Key Vendors 164
8.2 New Product Launch, Partnership, Investment, and M&A 167
8.3 Company Profiles 168
AstraZeneca plc 168
Bavarian Nordic A/S 171
China National Biotec Group Company Ltd. 174
CSL Ltd. 176
Daiichi Sankyo Co. Ltd 178
Emergent BioSolutions Inc. 180
GlaxoSmithKline plc 182
Johnson & Johnson 186
Merck & Co. 188
Moderna Inc. 190
Novavax, Inc. 191
Pfizer Inc. 193
Sanofi SA 197
Takeda Pharmaceutical Co. Ltd. 199
9 Investing in Global Market: Risk Assessment and Management 201
9.1 Risk Evaluation of Global Market 201
9.2 Critical Success Factors (CSFs) 204
Related Reports and Products 207
Table 1. Snapshot of Global Preventive Vaccines Market in Balanced Perspective, 2020-2026 19
Table 2. Growth Rate of World GDP, 2020-2022 24
Table 3. Main Product Trends and Market Opportunities in Global Preventive Vaccines Market 33
Table 4. Global Preventive Vaccines Market by Vaccine Type, 2016-2026, $ mn 41
Table 5. Global Preventive Vaccines Market by Disease, 2016-2026, $ mn 50
Table 6. COVID-19 Vaccines Authorized for Emergency Use or Approved for Full Use, as of April 2021 60
Table 7. Global Preventive Vaccines Market by Administration, 2016-2026, $ mn 63
Table 8. Global Preventive Vaccines Market by Patient, 2016-2026, $ mn 70
Table 9. Global Preventive Vaccines Market: Pediatric Vaccines by Disease, 2016-2026, $ mn 73
Table 10. Global Preventive Vaccines Market: Adult Vaccines by Disease, 2016-2026, $ mn 75
Table 11. Global Preventive Vaccines Market by Region, 2016-2026, $ mn 77
Table 12. Leading National Preventive Vaccines Market, 2020 and 2026, $ mn 79
Table 13. North America Preventive Vaccines Market by Country, 2016-2026, $ mn 82
Table 14. U.S. Preventive Vaccines Market by Vaccine Type, 2016-2026, $ mn 85
Table 15. U.S. Preventive Vaccines Market by Disease, 2016-2026, $ mn 85
Table 16. U.S. Preventive Vaccines Market by Administration, 2016-2026, $ mn 86
Table 17. Canada Preventive Vaccines Market by Vaccine Type, 2016-2026, $ mn 89
Table 18. Canada Preventive Vaccines Market by Disease, 2016-2026, $ mn 89
Table 19. Canada Preventive Vaccines Market by Administration, 2016-2026, $ mn 90
Table 20. Mexico Preventive Vaccines Market by Vaccine Type, 2016-2026, $ mn 92
Table 21. Mexico Preventive Vaccines Market by Disease, 2016-2026, $ mn 92
Table 22. Mexico Preventive Vaccines Market by Administration, 2016-2026, $ mn 93
Table 23. Europe Preventive Vaccines Market by Country, 2016-2026, $ mn 96
Table 24. UK Preventive Vaccines Market by Vaccine Type, 2016-2026, $ mn 98
Table 25. UK Preventive Vaccines Market by Disease, 2016-2026, $ mn 98
Table 26. UK Preventive Vaccines Market by Administration, 2016-2026, $ mn 99
Table 27. France Preventive Vaccines Market by Vaccine Type, 2016-2026, $ mn 101
Table 28. France Preventive Vaccines Market by Disease, 2016-2026, $ mn 101
Table 29. France Preventive Vaccines Market by Administration, 2016-2026, $ mn 102
Table 30. Germany Preventive Vaccines Market by Vaccine Type, 2016-2026, $ mn 104
Table 31. Germany Preventive Vaccines Market by Disease, 2016-2026, $ mn 104
Table 32. Germany Preventive Vaccines Market by Administration, 2016-2026, $ mn 105
Table 33. Spain Preventive Vaccines Market by Vaccine Type, 2016-2026, $ mn 107
Table 34. Spain Preventive Vaccines Market by Disease, 2016-2026, $ mn 107
Table 35. Spain Preventive Vaccines Market by Administration, 2016-2026, $ mn 108
Table 36. Italy Preventive Vaccines Market by Vaccine Type, 2016-2026, $ mn 110
Table 37. Italy Preventive Vaccines Market by Disease, 2016-2026, $ mn 110
Table 38. Italy Preventive Vaccines Market by Administration, 2016-2026, $ mn 111
Table 39. Russia Preventive Vaccines Market by Vaccine Type, 2016-2026, $ mn 113
Table 40. Germany Preventive Vaccines Market by Disease, 2016-2026, $ mn 113
Table 41. Germany Preventive Vaccines Market by Administration, 2016-2026, $ mn 114
Table 42. Preventive Vaccines Market in Rest of Europe by Country, 2016-2026, $ mn 116
Table 43. APAC Preventive Vaccines Market by Country, 2016-2026, $ mn 119
Table 44. China Preventive Vaccines Market by Vaccine Type, 2016-2026, $ mn 121
Table 45. China Preventive Vaccines Market by Disease, 2016-2026, $ mn 121
Table 46. China Preventive Vaccines Market by Administration, 2016-2026, $ mn 122
Table 47. Japan Preventive Vaccines Market by Vaccine Type, 2016-2026, $ mn 125
Table 48. Japan Preventive Vaccines Market by Disease, 2016-2026, $ mn 125
Table 49. Japan Preventive Vaccines Market by Administration, 2016-2026, $ mn 126
Table 50. India Preventive Vaccines Market by Vaccine Type, 2016-2026, $ mn 128
Table 51. India Preventive Vaccines Market by Disease, 2016-2026, $ mn 128
Table 52. India Preventive Vaccines Market by C Administration, 2016-2026, $ mn 129
Table 53. Australia Preventive Vaccines Market by Vaccine Type, 2016-2026, $ mn 131
Table 54. Australia Preventive Vaccines Market by Disease, 2016-2026, $ mn 131
Table 55. Australia Preventive Vaccines Market by Administration, 2016-2026, $ mn 132
Table 56. South Korea Preventive Vaccines Market by Vaccine Type, 2016-2026, $ mn 134
Table 57. South Korea Preventive Vaccines Market by Disease, 2016-2026, $ mn 134
Table 58. South Korea Preventive Vaccines Market by Administration, 2016-2026, $ mn 135
Table 59. Preventive Vaccines Market in Rest of APAC by Country, 2016-2026, $ mn 137
Table 60. South America Preventive Vaccines Market by Country, 2016-2026, $ mn 140
Table 61. Argentina Preventive Vaccines Market by Vaccine Type, 2016-2026, $ mn 142
Table 62. Argentina Preventive Vaccines Market by Disease, 2016-2026, $ mn 142
Table 63. Argentina Preventive Vaccines Market by Administration, 2016-2026, $ mn 143
Table 64. Brazil Preventive Vaccines Market by Vaccine Type, 2016-2026, $ mn 145
Table 65. Brazil Preventive Vaccines Market by Disease, 2016-2026, $ mn 145
Table 66. Brazil Preventive Vaccines Market by Administration, 2016-2026, $ mn 146
Table 67. Colombia Preventive Vaccines Market by Vaccine Type, 2016-2026, $ mn 148
Table 68. Mexico Preventive Vaccines Market by Disease, 2016-2026, $ mn 148
Table 69. Mexico Preventive Vaccines Market by Administration, 2016-2026, $ mn 149
Table 70. MEA Preventive Vaccines Market by Country, 2016-2026, $ mn 153
Table 71. UAE Preventive Vaccines Market by Vaccine Type, 2016-2026, $ mn 155
Table 72. UAE Preventive Vaccines Market by Disease, 2016-2026, $ mn 155
Table 73. UAE Preventive Vaccines Market by Administration, 2016-2026, $ mn 156
Table 74. Saudi Arabia Preventive Vaccines Market by Vaccine Type, 2016-2026, $ mn 158
Table 75. Saudi Arabia Preventive Vaccines Market by Disease, 2016-2026, $ mn 158
Table 76. Saudi Arabia Preventive Vaccines Market by Administration, 2016-2026, $ mn 159
Table 77. Egypt Preventive Vaccines Market by Vaccine Type, 2016-2026, $ mn 161
Table 78. Egypt Preventive Vaccines Market by Disease, 2016-2026, $ mn 161
Table 79. Egypt Preventive Vaccines Market by Administration, 2016-2026, $ mn 162
Table 80. AstraZeneca plc: Company Snapshot 168
Table 81. AstraZeneca plc: Revenue, 2018-2020, $ bn 169
Table 82. Bavarian Nordic A/S: Company Snapshot 171
Table 83. Bavarian Nordic A/S: Marketed Products and Pipeline, as of July 2020 172
Table 84. China National Biotec Group Company Ltd.: Company Snapshot 174
Table 85. CSL Ltd.: Company Snapshot 176
Table 86. Daiichi Sankyo Co. Ltd.: Company Snapshot 178
Table 87. Emergent BioSolutions Inc.: Company Snapshot 180
Table 88. GlaxoSmithKline: Company Snapshot 182
Table 89. GlaxoSmithKline: Business Segmentation 183
Table 90. GlaxoSmithKline: Product Portfolio 184
Table 91. GlaxoSmithKline: Revenue, 2018-2020, $ bn 185
Table 92. GlaxoSmithKline: Recent Developments 185
Table 93. Johnson & Johnson: Company Snapshot 186
Table 94. Johnson & Johnson: Business Segments 187
Table 95. Merck & Co., Inc.: Company Snapshot 188
Table 96. Merck & Co., Inc.: Business Segmentation 188
Table 97. Merck & Co., Inc.: Revenue, 2018-2020, $ bn 189
Table 98. Moderna Inc.: Company Snapshot 190
Table 99. Novavax, Inc.: Company Snapshot 191
Table 100. Pfizer Inc.: Company Snapshot 193
Table 101. Pfizer Inc.: Business Segmentation 194
Table 102. Pfizer Inc.: Product Portfolio 195
Table 103. Pfizer Inc.: Revenue, 2018-2020, $ bn 196
Table 104. Pfizer Inc.: Recent Developments 196
Table 105. Sanofi: Company Snapshot 197
Table 106. Sanofi: Business Segmentation 197
Table 107. Sanofi: Revenue, 2018-2020, $ bn 198
Table 108. Takeda Pharmaceutical Co. Ltd.: Company Snapshot 199
Table 109. Risk Evaluation for Investing in Global Market, 2020-2026 202
Table 110. Critical Success Factors and Key Takeaways 205
